Last reviewed · How we verify
Acurox 7.5/30
Acurox 7.5/30 is a combination of oxycodone and acetaminophen designed with abuse-deterrent technology to reduce the risk of misuse and overdose.
Acurox 7.5/30 is a combination of oxycodone and acetaminophen designed with abuse-deterrent technology to reduce the risk of misuse and overdose. Used for Moderate to severe acute pain.
At a glance
| Generic name | Acurox 7.5/30 |
|---|---|
| Also known as | oxycodone/niacin 7.5/30mg |
| Sponsor | Acura Pharmaceuticals Inc. |
| Drug class | Opioid analgesic combination with abuse-deterrent formulation |
| Target | Mu-opioid receptor (oxycodone component) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
The drug combines oxycodone, a mu-opioid receptor agonist that provides analgesia, with acetaminophen, a non-opioid analgesic that enhances pain relief. Acura Pharmaceuticals' proprietary abuse-deterrent formulation aims to make the oxycodone component difficult to extract or misuse via non-oral routes, thereby reducing potential for opioid abuse while maintaining therapeutic efficacy for pain management.
Approved indications
- Moderate to severe acute pain
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acurox 7.5/30 CI brief — competitive landscape report
- Acurox 7.5/30 updates RSS · CI watch RSS
- Acura Pharmaceuticals Inc. portfolio CI